Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roswitha Runge

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Pharmaceuticals (Basel, Switzerland)|December 23, 2023
Combining Cisplatin with Different Radiation Qualities-Interpretation of Cytotoxic Effects In Vitro by Isobolographic AnalysisRoswitha Runge, Falco Reissig, Nora Herzog, et al.
International Journal of Radiation Biology|April 28, 2016
Comparison of the radiotoxicity of the <sup>99m</sup>Tc-labeled compounds <sup>99m</sup>Tc-pertechnetate, <sup>99m</sup>Tc-HMPAO and <sup>99m</sup>Tc-MIBIUte Maucksch, Roswitha Runge, Gerd Wunderlich, et al.
International Journal of Molecular Sciences|December 11, 2022
Psoralen as a Photosensitizers for Photodynamic Therapy by Means of In Vitro Cherenkov LightLisa Hübinger, Roswitha Runge, Tobias Rosenberg, et al.
Nuklearmedizin. Nuclear Medicine|August 7, 2019
Induction and rejoining of DNA double-strand breaks in the lymphocytes of prostate cancer patients after radium-223 treatment as assessed by the γH2AX foci assayRoswitha Runge, Liane Oehme, Sabine Grosche-Schlee, et al.
Nuclear Medicine Communications|June 17, 2009
Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancerKnut Liepe, Hans Heiner Geidel, Ralf Bergmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2003
Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastasesKnut Liepe, Reiner Hliscs, Joachim Kropp, et al.
Plos One|August 8, 2014
99mTc-labeled HYNIC-DAPI causes plasmid DNA damage with high efficiencyJoerg Kotzerke, Robert Punzet, Roswitha Runge, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2024
Enhancing Effects of Olaparib by Alpha- and Beta-Emitting Radionuclides, X-Rays, and Ultraviolet A Light in Combination with Ortho-IodoHoechst in a Prostate Cancer Cell ModelAndrea C Luna Mass, Roswitha Runge, Kerstin Wetzig, et al.
Cancers|May 28, 2022
Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic StrategyJoerg Kotzerke, Dorothee Buesser, Anne Naumann, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
Influence of the Molar Activity of <sup>203/212</sup>Pb-PSC-PEG<sub>2</sub>-TOC on Somatostatin Receptor Type 2-Binding and Cell UptakeMarc Pretze, Enrico Michler, Roswitha Runge, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Pharmaceuticals (Basel, Switzerland)|December 23, 2023
Combining Cisplatin with Different Radiation Qualities-Interpretation of Cytotoxic Effects In Vitro by Isobolographic AnalysisRoswitha Runge, Falco Reissig, Nora Herzog, et al.
International Journal of Radiation Biology|April 28, 2016
Comparison of the radiotoxicity of the <sup>99m</sup>Tc-labeled compounds <sup>99m</sup>Tc-pertechnetate, <sup>99m</sup>Tc-HMPAO and <sup>99m</sup>Tc-MIBIUte Maucksch, Roswitha Runge, Gerd Wunderlich, et al.
International Journal of Molecular Sciences|December 11, 2022
Psoralen as a Photosensitizers for Photodynamic Therapy by Means of In Vitro Cherenkov LightLisa Hübinger, Roswitha Runge, Tobias Rosenberg, et al.
Nuklearmedizin. Nuclear Medicine|August 7, 2019
Induction and rejoining of DNA double-strand breaks in the lymphocytes of prostate cancer patients after radium-223 treatment as assessed by the γH2AX foci assayRoswitha Runge, Liane Oehme, Sabine Grosche-Schlee, et al.
Nuclear Medicine Communications|June 17, 2009
Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancerKnut Liepe, Hans Heiner Geidel, Ralf Bergmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2003
Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastasesKnut Liepe, Reiner Hliscs, Joachim Kropp, et al.
Plos One|August 8, 2014
99mTc-labeled HYNIC-DAPI causes plasmid DNA damage with high efficiencyJoerg Kotzerke, Robert Punzet, Roswitha Runge, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2024
Enhancing Effects of Olaparib by Alpha- and Beta-Emitting Radionuclides, X-Rays, and Ultraviolet A Light in Combination with Ortho-IodoHoechst in a Prostate Cancer Cell ModelAndrea C Luna Mass, Roswitha Runge, Kerstin Wetzig, et al.
Cancers|May 28, 2022
Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic StrategyJoerg Kotzerke, Dorothee Buesser, Anne Naumann, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
Influence of the Molar Activity of <sup>203/212</sup>Pb-PSC-PEG<sub>2</sub>-TOC on Somatostatin Receptor Type 2-Binding and Cell UptakeMarc Pretze, Enrico Michler, Roswitha Runge, et al.
Pageof 3